Clinical Trials Logo
  1. Home
  2. Rectal Cancer Stage III
  3. NCT05495308

"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".

Rectal Cancer Stage III Clinical Trial

Official title:
Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and pCR After Neoadjuvant Treatment.

Clinical Trial Summary

Pathologic complete response (pCR) after multimodal treatment for locally advanced rectal cancer (LARC) patients is considered as the gold-standard of treatment success as it is associated to privileged oncologic outcome. Nevertheless, data from multicenter high-volume cohorts with long term follow-up are scarce. This is a multicenter observational study using prospectively collected data from the Spanish Rectal Cancer Project database. The main objective of the study is to update long-term oncologic follow-up of those patients treated for LARC with nCRT and surgery (either TME or subtotal TME; S-TME) who had obtained a pCR. Secondary objective is to analyze demographic, clinical, operative and treatment variables in search of related factors to adverse oncologic outcomes, like distant recurrence or tumor-related deaths. The results are reported in accordance with the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) Statement for observational studies. All calculations are performed using Stata 13.1 (StataCorp, Texas, USA).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05495308
Study type Observational [Patient Registry]
Source Hospital San Carlos, Madrid
Contact
Status Completed
Phase
Start date September 1, 2021
Completion date May 1, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04598984 - The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
Active, not recruiting NCT04246684 - Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients Phase 3
Completed NCT05723965 - Using Artificial Intelligence to Predict Rectal Cancer Outcomes
Not yet recruiting NCT05830890 - Sentinel Lymph Node Biopsy in Rectal Cancer N/A
Active, not recruiting NCT04503694 - Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer Phase 2
Completed NCT02363374 - Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer Phase 2
Recruiting NCT03561142 - Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. Phase 2
Completed NCT03602079 - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Phase 1/Phase 2
Recruiting NCT05148767 - UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer Phase 4
Recruiting NCT06254521 - The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer Phase 2
Completed NCT01325649 - Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma N/A
Recruiting NCT04970498 - Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Active, not recruiting NCT03840239 - TNT to Increase the Clinical Complete Response Rate for Distal LARC Phase 2
Active, not recruiting NCT03391843 - Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer Phase 2